Lemaitre Vascular Inc (LMAT) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Lemaitre Vascular Inc   (NASDAQ: LMAT)


Lemaitre Vascular Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Lemaitre Vascular Inc's ROI in the second quarter of 2026?
Lemaitre Vascular Inc achieved a return on average invested assets (ROI) of 11.51 % in its second quarter of 2026, this is above LMAT's average return on investment of 10.39%.
Lemaitre Vascular Inc invested over the 12 months ending in its second quarter of 2026 $588 million

ROI has improved compared to 10.91% in the first quarter of 2026, due to net income growth.

Within the Healthcare sector 94 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 764 to 773.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 22.73 % 35.29 % 51.18 % 69.92 % 56.61 %
Y / Y Net Income Change TTM 43.64 % 38.17 % 69.06 % 132.23 % 298.4 %
Investment (TTM) in Millions 611 596 580 565 547
Return On Investment (TTM) 11.51 % 10.91 % 10.39 % 9.93 % 9.84 %
LMAT's Overall Ranking # 773 # 764 # 578 # 412 # 631
Seq. Investment Change TTM 2.79 % 2.92 % 3.44 % 12.15 % 13.31 %
Seq. Net Income Change TTM 8.45 % 8.09 % 8.25 % 13.2 % 4.32 %
Net Income (TTM) in Millions 68 62 58 53 47

LMAT Company Profile >> Back to LMAT Roi Comparisons >> See Annual LMAT Return On Investment



Return On Investment LMAT's Ranking
Within: No.
Industry # 26
Sector # 95
Overall # 773

Return On Investment Statistics
High Average Low
18.94 %
10.39 %
3.68 %
(Jun 30 2018)   (Mar 31 2014)







Financial Statements
Lemaitre Vascular Inc's II. Quarter Investments $ 611 Millions LMAT's Balance sheet
Lemaitre Vascular Inc's II. Quarter Income $ 19 Millions Quarterly LMAT's Income Statement
LMAT's Income by Division See LMAT's Income by Division


LMAT Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 564 506 300 270 257
Y / Y Investment Growth 11.41 % 68.54 % 11.02 % 5.26 % 20.73 %
Net Income in Millions 58 44 30 21 27
Y / Y Net Income Growth 31.1 % 46.28 % 45.89 % -23.31 % 26.8 %
Annual Return On Investment 10.24 % 8.71 % 10.03 % 7.63 % 10.48 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 10.24 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
LMAT's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for LMAT's Competitors
Subscribers only: Roi for Lemaitre Vascular Inc's Suppliers
Subscribers only: Return On Investment for LMAT's Customers

Other Ratios
LMAT's Roa LMAT's Inventory Turnover Ratio LMAT's Growth Rates LMAT's Dividend Statistics
LMAT's Profitability Ratios LMAT's Asset Turnover Ratio LMAT's Dividend Growth
LMAT's Roe LMAT's Valuation Ratios LMAT's Financial Strength Ratios LMAT's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Acadia Pharmaceuticals Inc   31.05 %
Caredx Inc   29.42 %
Adma Biologics Inc   28.94 %
Protalix Biotherapeutics inc   25.72 %
Pro dex Inc   24.29 %
Innoviva Inc   23.33 %
Electromed Inc   23.18 %
Zevra Therapeutics Inc   22.90 %
Iradimed Corporation  22.57 %
Alnylam Pharmaceuticals Inc   22.10 %
Eton Pharmaceuticals Inc   21.31 %
Dexcom Inc   20.98 %
Healthcare Services Group Inc   20.93 %
Arcutis Biotherapeutics Inc   20.77 %
Chemed Corporation  20.13 %
Resmed Inc   20.01 %
Halozyme Therapeutics Inc   19.99 %
Vertex Pharmaceuticals Inc  19.97 %
Agilent Technologies inc   19.84 %
Illumina Inc   19.61 %
Puma Biotechnology Inc   19.60 %
United Therapeutics Corporation  19.53 %
Zoetis Inc   19.44 %
Krystal Biotech Inc   19.16 %
Carlisle Companies Incorporated  18.88 %
Neurocrine Biosciences Inc   17.51 %
Intuitive Surgical Inc   17.11 %
Theravance Biopharma inc   17.10 %
Standard Biotools Inc   16.38 %
Inspire Medical Systems inc   16.34 %

Date modified: 2026-09-11T09:47:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.